Search results
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 2 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 23 hours agoResults for the ACE-Breast-02 study were presented at the American Society of Clinical Oncology 2024...
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
Zacks via Yahoo Finance· 10 months agoSeagen Inc. SGEN announced positive top-line results from its late-stage HER2CLIMB-02 study,...
Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal
Zacks via Yahoo Finance· 1 year agoRoche Holding AG’s RHHBY performance in 2022 was pretty average, as the demand for COVID-19 products...
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
Zacks via Yahoo Finance· 2 weeks agoRoche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced...
Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales
Zacks via Yahoo Finance· 2 years agoSwiss pharma giant Roche Holding AG’s RHHBY third-quarter revenues declined 6% to CHF 14.7 billion...
Seagen's breast cancer therapy succeeds in late-stage study
Reuters via Yahoo News· 10 months agoPfizer in March agreed to acquire Seagen and its targeted therapies in a $43 billion deal to help...
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
Zacks via Yahoo Finance· 6 months agoRoche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone...
Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales
Zacks via Yahoo Finance· 10 months agoRoche Holding AG’s RHHBY performance in the first half was average, as COVID-19 product related...
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Zacks via Yahoo Finance· 2 years agoShares of Puma Biotechnology PBYI were up 17.4% at market close on Aug 5, following the earnings...